PDCD1 and hepatocellular carcinoma: At the same time, in tumor mouse models, inhibition of MCT4 can significantly enhance the therapeutic effect of PD-1 immune checkpoint inhibitors [107], which indicates that the combined use of MCT4 inhibitors may provide opportunities for immunotherapy-resistant HCC patients.